{'fraction_non_alphanumeric': 0.03873239436619718, 'fraction_numerical': 0.027288732394366196, 'mean_word_length': 5.112903225806452, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
In-vitro activity of cefepime and seven other antimicrobial agents against 1518 non-fermentative Gram-negative bacilli collected from 48 Canadian health care facilities. Canadian Afermenter Study Group.

Non-fermentative bacilli are primarily nosocomial pathogens, and are also often resistant in vitro to a broad range of antimicrobial agents. In this large Canadian study, we collected 1466 clinical, non-repeat isolates of Pseudomonas aeruginosa, 21 of Acinetobacter spp. and 31 Stenotrophomas maltophilia. MICs of eight antibiotics were determined by the NCCLS microdilution method in a central laboratory. Tobramycin was the most active agent against P. aeruginosa (94.5% susceptible); amikacin and imipenem were the most active against Acetinobacter spp. (100%) and ceftazidime was the most active against S. maltophilia (40.6%). Against each group of isolates, cefepime was active against 87, 86.4 and 15.6%, respectively. This in-vitro study showed that cefepime may be a useful additional agent in the treatment of infections caused by P. aeruginosa and Acinetobacter spp., but not when S. maltophilia is considered pathogenic.